For the prevention of five clostridial diseases [enterotoxaemia (pulpy kidney), blackleg, malignant oedema, black disease, tetanus] and caseous lymphadenitis (“lympho” or cheesy gland), and the treatment and control of internal parasites and nasal bot of adult sheep.
EWEGUARD contains moxidectin, a member of the milbemycin/avermectin family. It is effective against sensitive strains of the following internal parasites (adult and immature stages unless otherwise stated):
- Haemonchus contortus (barber’s pole worm)
- Ostertagia (Teladorsagia) circumcincta (small brown stomach worm)
- Ostertagia trifurcata
- Trichostrongylus axei (stomach hair worm)
- Trichostrongylus colubriformis (black scour worm)
- Nematodirus spp (thin necked intestinal worm)
- Cooperia spp (small intestinal worm) (adults only)
- Oesophagostomum venulosum (large bowel worm) (adults only)
- Chabertia ovina (large mouthed bowel worm)
- Trichuris ovis (whip worm) (adults only)
- Dictyocaulus filaria (large lungworm)
Including inhibited or hypobiotic larvae of Haemonchus, Ostertagia and Trichostrongylus.
- Oestrus ovis (nasal bot)
EWEGUARD, when used at the recommended dose rate, prevents reinfection with Haemonchus contortus and Ostertagia circumcincta for at least 35 days, and Trichostrongylus colubriformis for at least 7 days following a single subcutaneous injection.
- Convenient combination of long acting worm control and 6 in 1 vaccine
- Ensures high levels of protective antibodies can be passed to lambs via the ewes' colostrum
- Single shot prelamb treatment
- Prevents the periparturient rise in worm egg output, keeping pastures cleaner
- Provides 35 days persistent activity against barber's pole worm and Ostertagia circumcincta and 7 days persistent activity against Trichostrongylus colubriformis
- Proven in New Zealand studies to increase productivity (increase in lamb liveweight per ewe treated)
Available in 500mL flexipacks.
By law the user must take due care, obtaining expert advice when necessary, to avoid unnecessary pain and distress when using the product other than as directed on the label.
To give 0.2 mg moxidectin/kg liveweight:
- For animals up to 50 kg liveweight give 2 mL subcutaneously.
- For animals over 50 kg liveweight give 1 mL per 25 kg subcutaneously.
As a guide use the following dosage schedule:
Body Weight (kg)
Dose volume (mL)
Sheep over 75 kg to be dosed at 1 mL per 25 kg.
Shake well before use and keep thoroughly mixed during use. This product must be administered by subcutaneous injection in the anterior half of the neck. Correct injection technique should be used. A representative sample of animals should be weighed before treatment. Dose to the heaviest animal by liveweight in each group (ewes, wethers, rams). Do not underdose. Where there is a large variation in size within the group, the dose rate should be based on the label directions for each weight range. Drafting into two or more lines may be appropriate to avoid excessive overdosing.
Full active immune response requires 2 injections. A priming dose must be followed by a secondary dose 4 to 6 weeks later to produce maximum response.
The initial immunising course of 2 injections 4 to 6 weeks apart should be followed by an annual booster injection to maintain immunity.
- Previously vaccinated ewes: administer EWEGUARD two to three weeks before lambing. This will ensure that a high level of protective antibodies is passed to the lambs in the colostrum.
- Unvaccinated ewes, rams and wethers: administer 2 doses of EWEGUARD, four to six weeks apart.
EWEGUARD is for the vaccination of adult stock only.
The use of EWEGUARD will:
- treat existing worm infections;
- provide protection against reinfection in treated animals;
- prevent the rise in worm egg output of ewes at lambing time;
- reduce pasture contamination with worm eggs in the lambing paddock.
Ask your local veterinary practitioner or animal health advisor for recommended parasite management practices for your area to reduce development of resistance. It is advisable that a resistance test be conducted regularly when using any parasite treatment.
The manufacturer advises that EWEGUARD should not be used in sheep that have been vaccinated with footrot vaccine. These sheep may be sensitised and subsequent treatment with EWEGUARD can lead to a hypersensitivity reaction.
Vaccination of ewes initiates an immune reaction. It is essential that the ewe mounts an immune reaction in response to the vaccine to ensure optimum antibody production for protection of both the ewe and her lamb(s). In order to minimise or eliminate any adverse effects resulting from this physiological response to vaccination when using EWEGUARD, the following management procedures are recommended:
- Ensure ewes are well fed prior to yarding for vaccination;
- Keep the time ewes are yarded and off-feed to the minimum required for vaccination;
- Feed ewes well following vaccination. The first 2-3 days after vaccination are the most crucial;
- Minimise stress on the ewes when they are mustered and yarded for vaccination.
Store between 2° and 8°C. (Refrigerate. DO NOT FREEZE). Protect from light.
It is an offence for users of this product to cause residues exceeding the relevant MRL in the NZ (Maximum Residues Limits of Agricultural Compounds) Food Standards.
Meat: Sheep producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 49 days of the last treatment.
Milk: Milk intended for sale for human consumption must be discarded during treatment and for 49 days following the last treatment.
Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. EWEGUARD is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A7302.
NZ Technical Services 0800 650 277
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.